Manufacturer of Pembrolizumab

Pembrolizumab is produced by Merck, a world-renowned pharmaceutical company headquartered in New Jersey, USA. Its trade name is Keytruda. Patients can use it to treat non-small cell lung cancer, melanoma skin cancer, bladder cancer, Hodgkin lymphoma, etc., and may also receive pembrolizumab as part of a clinical trial for another cancer.

Pembrolizumab is an immunotherapy that stimulates the body's immune system to fight cancer cells. Embrolizumab, the active ingredient in pembrolizumab, targets and blocks a protein called PD-1 on the surface of certain immune cells called T cells. By blocking PD-1, it triggers the T cells to find and kill cancer cells. Doctors will allow patients to receive pembrolizumab injection every3-6 weeks, each time taking about30 minutes. As long as pembrolizumab is effective and the side effects are not too severe,patients can use it.

PembrolizumabThe original drug is already on the market in China. SpecificationsThe price per box of 100mg/4ml may be around RMB 15,000. This drug is a strictly controlled drug and has not yet been included in medical insurance. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.